Correlation Engine 2.0
Clear Search sequence regions

  • apoptosis (1)
  • ASNS (4)
  • CGA (2)
  • cisplatin (10)
  • dna damage (1)
  • eIF3a (2)
  • gene (3)
  • humans (1)
  • metalloproteinases (2)
  • MMP19 (5)
  • patients (2)
  • platinum (2)
  • Sizes of these terms reflect their relevance to your search.

    Platinum-based concurrent chemoradiotherapy is considered a standard treatment approach for locoregionally advanced nasopharyngeal carcinoma. However, only a minority of patients benefit from this treatment regimen compared with radiotherapy alone. Identification of a set of molecular markers predicting sensitivity of platinum-based chemotherapy may contribute to personalized treatment of patients with nasopharyngeal carcinoma for better clinical outcome with less toxicity. Previously, we generated a cisplatin-sensitive nasopharyngeal carcinoma cell line, S16, by clonal selection from CNE-2 cells and found that eIF3a is upregulated and contributes to cisplatin sensitivity by downregulating the synthesis of nucleotide excision repair proteins. In this study, we conducted a gene expression profiling analysis and found three other genes, asparagine synthetase (ASNS), choriogonadotropin α subunit (CGA), and matrix metalloproteinase 19 (MMP19), that are upregulated in the cisplatin-sensitive S16 cells compared with the CNE-2 cells. However, only ASNS and MMP19, but not CGA, contributes to cisplatin sensitivity by potentiating cisplatin-induced DNA damage and apoptosis. Thus, ASNS and MMP19, along with eIF3a, are the sensitivity factors for cisplatin treatment and may serve as potential candidate molecular markers for predicting cisplatin sensitivity of advanced nasopharyngeal carcinoma. ©2013 AACR.


    Ran-Yi Liu, Zizheng Dong, Jianguo Liu, Ling Zhou, Wenlin Huang, Sok Kean Khoo, Zhongfa Zhang, David Petillo, Bin Tean Teh, Chao-Nan Qian, Jian-Ting Zhang. Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells. Molecular cancer therapeutics. 2013 Oct;12(10):2157-66

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 23956056

    View Full Text